Exact Mass: 469.1559
Exact Mass Matches: 469.1559
Found 408 metabolites which its exact mass value is equals to given mass value 469.1559
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Indol-3-ylacetyl-myo-inositol L-arabinoside
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
O-Methyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate
O-Methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]thiocarbamate is a fully acetylated thiocarbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables. The trans and cis rotamers differ in the orientation of the NH group with respect to sulfur.
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
Bucladesine
Dacomitinib
Ethanol and folate
Oxaprozin glucuronide
RO4929097
D004791 - Enzyme Inhibitors > D000091062 - Gamma Secretase Inhibitors and Modulators
2-[1-[4,5-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]indol-3-yl]acetic acid
O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (E)|O-methyl-4-<(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl>thiocarbamate (Z)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (E)|O-methyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyloxy)benzyl]thiocarbamate (Z)
5-O-beta-D-glucopyranosyl-dihydroABG|5-O-beta-D-glucopyranosyl-dihydroascorbigen
His Asn Ala Glu
Bucladesine
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CE - Phosphodiesterase inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
SRT 1720
SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
Asn Ala His Glu
Gln Ala His Asp
C24H27N3O7_Prolinamide, N-(4-hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)
3-hydroxy-2-[[1-[2-[(4-hydroxybenzoyl)amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]benzoic acid
Ala Cys Asn Tyr
Ala Cys Tyr Asn
Ala Asp His Gln
Ala Asp Gln His
Ala Glu His Asn
Ala Glu Asn His
Ala His Asp Gln
Ala His Glu Asn
Ala His Asn Glu
Ala His Gln Asp
Ala Asn Cys Tyr
Ala Asn Glu His
Ala Asn His Glu
Ala Asn Tyr Cys
Ala Gln Asp His
Ala Gln His Asp
Ala Tyr Cys Asn
Ala Tyr Asn Cys
Cys Ala Asn Tyr
Cys Ala Tyr Asn
Cys Cys Met Asn
Cys Cys Asn Met
Cys Phe Asn Ser
Cys Phe Ser Asn
Cys Gly Lys Tyr
Cys Gly Gln Tyr
Cys Gly Tyr Lys
Cys Gly Tyr Gln
Cys His Asn Pro
Cys His Pro Asn
Cys Lys Gly Tyr
Cys Lys Tyr Gly
Cys Met Cys Asn
Cys Met Asn Cys
Cys Asn Ala Tyr
Cys Asn Cys Met
Cys Asn Phe Ser
Cys Asn His Pro
Cys Asn Met Cys
Cys Asn Pro His
Cys Asn Ser Phe
Cys Asn Tyr Ala
Cys Pro His Asn
Cys Pro Asn His
Cys Gln Gly Tyr
Cys Gln Tyr Gly
Cys Ser Phe Asn
Cys Ser Asn Phe
Cys Tyr Ala Asn
Cys Tyr Gly Lys
Cys Tyr Gly Gln
Cys Tyr Lys Gly
Cys Tyr Asn Ala
Cys Tyr Gln Gly
Asp Ala His Gln
Asp Ala Gln His
Asp His Ala Gln
Asp His Gln Ala
Asp Gln Ala His
Asp Gln His Ala
Glu Ala His Asn
Glu Ala Asn His
Glu Gly His Gln
Glu Gly Gln His
Glu His Ala Asn
Glu His Gly Gln
Glu His Asn Ala
Glu His Gln Gly
Glu Asn Ala His
Glu Asn His Ala
Glu Gln Gly His
Glu Gln His Gly
Phe Cys Asn Ser
Phe Cys Ser Asn
Phe Asn Cys Ser
Phe Asn Ser Cys
Phe Ser Cys Asn
Phe Ser Asn Cys
Gly Cys Lys Tyr
Gly Cys Gln Tyr
Gly Cys Tyr Lys
Gly Cys Tyr Gln
Gly Glu His Gln
Gly Glu Gln His
Gly His Glu Gln
Gly His Gln Glu
Gly Lys Cys Tyr
Gly Lys Tyr Cys
Gly Gln Cys Tyr
Gly Gln Glu His
Gly Gln His Glu
Gly Gln Tyr Cys
Gly Tyr Cys Lys
Gly Tyr Cys Gln
Gly Tyr Lys Cys
Gly Tyr Gln Cys
His Ala Asp Gln
His Ala Glu Asn
His Ala Asn Glu
His Ala Gln Asp
His Cys Asn Pro
His Cys Pro Asn
His Asp Ala Gln
His Asp Gln Ala
His Glu Ala Asn
His Glu Gly Gln
His Glu Asn Ala
His Glu Gln Gly
His Gly Glu Gln
His Gly Gln Glu
His Asn Cys Pro
His Asn Glu Ala
His Asn Pro Cys
His Pro Cys Asn
His Pro Asn Cys
His Gln Ala Asp
His Gln Asp Ala
His Gln Glu Gly
His Gln Gly Glu
Lys Cys Gly Tyr
Lys Cys Tyr Gly
Lys Gly Cys Tyr
Lys Gly Tyr Cys
Lys Tyr Cys Gly
Lys Tyr Gly Cys
Met Cys Cys Asn
Met Cys Asn Cys
Met Asn Cys Cys
Asn Ala Cys Tyr
Asn Ala Glu His
Asn Ala Tyr Cys
Asn Cys Ala Tyr
Asn Cys Cys Met
Asn Cys Phe Ser
Asn Cys His Pro
Asn Cys Met Cys
Asn Cys Pro His
Asn Cys Ser Phe
Asn Cys Tyr Ala
Asn Glu Ala His
Asn Glu His Ala
Asn Phe Cys Ser
Asn Phe Ser Cys
Asn His Ala Glu
Asn His Cys Pro
Asn His Glu Ala
Asn His Pro Cys
Asn Met Cys Cys
Asn Pro Cys His
Asn Pro His Cys
Asn Ser Cys Phe
Asn Ser Phe Cys
Asn Ser Ser Tyr
Asn Ser Tyr Ser
Asn Tyr Ala Cys
Asn Tyr Cys Ala
Asn Tyr Ser Ser
Pro Cys His Asn
Pro Cys Asn His
Pro His Cys Asn
Pro His Asn Cys
Pro Asn Cys His
Pro Asn His Cys
Gln Ala Asp His
Gln Cys Gly Tyr
Gln Cys Tyr Gly
Gln Asp Ala His
Gln Asp His Ala
Gln Glu Gly His
Gln Glu His Gly
Gln Gly Cys Tyr
Gln Gly Glu His
Gln Gly His Glu
Gln Gly Tyr Cys
Gln His Ala Asp
Gln His Asp Ala
Gln His Glu Gly
Gln His Gly Glu
Gln Tyr Cys Gly
Gln Tyr Gly Cys
Ser Cys Phe Asn
Ser Cys Asn Phe
Ser Phe Cys Asn
Ser Phe Asn Cys
Ser Asn Cys Phe
Ser Asn Phe Cys
Ser Asn Ser Tyr
Ser Asn Tyr Ser
Ser Ser Asn Tyr
Ser Ser Tyr Asn
Ser Tyr Asn Ser
Ser Tyr Ser Asn
Tyr Ala Cys Asn
Tyr Ala Asn Cys
Tyr Cys Ala Asn
Tyr Cys Gly Lys
Tyr Cys Gly Gln
Tyr Cys Lys Gly
Tyr Cys Asn Ala
Tyr Cys Gln Gly
Tyr Gly Cys Lys
Tyr Gly Cys Gln
Tyr Gly Lys Cys
Tyr Gly Gln Cys
Tyr Lys Cys Gly
Tyr Lys Gly Cys
Tyr Asn Ala Cys
Tyr Asn Cys Ala
Tyr Asn Ser Ser
Tyr Gln Cys Gly
Tyr Gln Gly Cys
Tyr Ser Asn Ser
Tyr Ser Ser Asn
NVP-BEZ235
N-(4-Hydroxybenzoyl)valyl-N-(2-carboxy-6-hydroxyphenyl)prolinamide
Belotecan hydrochloride
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D004791 - Enzyme Inhibitors
1-[2-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl]ethylamino]ethyl]pyridinium acetate
b-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
Dacomitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
fmoc-(s)-3-amino-4-(2-trifluoromethyl-phenyl)-butyric acid
BENZENE, 1,1-[(4-NITROPHENYL)METHYLENE]BIS[2,4,6-TRIMETHOXY]-
2-Nitrophenyl2,3-di-O-acetyl-4-O-triethylsilyl-b-D-xylopyranoside
Fmoc-(S)-3-Amino-4-(4-trifluoromethylphenyl)-butyric acid
dimenhydrinate
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use > R06AA - Aminoalkyl ethers C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Dimenhydrinate is an orally active H1-antihistamine consisting of Diphenhydramine (HY-B0303) and 8-Chlorotheophylline. Dimenhydrinate is used to prevent nausea, vomiting, dizziness, and vertigo associated with motion sickness[1].
Fmoc-(R)-3-Amino-4-(2-trifluoromethylphenyl)-butyric acid
Fmoc-(R)-3-Amino-4-(4-trifluoromethyl-phenyl)-butyric acid
Fmoc-(S)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
Almotriptan
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine. IC50: Target: 5-hydroxytryptamine1B/1D (5-HT1B/1D) Receptor Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults. Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less. Almotriptan did not exhibit significant affinity for several non-5-HT receptors studied up to 100 microM. Almotriptan inhibited forskolin-stimulated cyclic AMP accumulation in HeLa cells transfected with 5-HT(1B) or 5-HT(1D) human receptors [1]. Almotriptan had a mild antiemetic effect and a slight, transient diuretic effect in dogs, although the latter effect is probably of no clinical relevance. In addition, no effect on the respiratory system of conscious guinea pigs was observed following almotriptan treatment. These results indicate that almotriptan has a favourable safety profile with respect to the central nervous, renal and respiratory systems [2].
a-D-Galactopyranoside,4-nitrophenyl, 2,3,4,6-tetraacetate
benzylpenicillin β-diethylaminoethyl ester hydrochloride
4-nitrophenyl tetra-o-acetyl-beta-d-glucopyranoside
Gandotinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(2R,3S,4R,5R)-2-(hydroxyMethyl)-5-(6-((2-(Methylthio)ethyl)aMino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
Fmoc-(R)-3-Amino-4-(3-trifluoromethylphenyl)-butyric acid
2-(2-phenyl-9H-carbazol-9-yl)dibenzo[b,d]thiophen-4-ylboronic acid
D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylMethyl)-, 1,6-diacetate
4-[(4-Chlorophenyl)-2-pyridylmethoxy]piperidine p-nitrobenzoic acid salt
(E)-N-(4-(3-(tert-Butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxystyryl)phenyl)methanesulfonamide
4H-1,2,4-Triazole, 3-(4-(3-(ethylsulfonyl)propyl)bicyclo(2.2.2)oct-1-yl)-4-methyl-5-(2-(trifluoromethyl)phenyl)-
Mycophenolate mofetil hydrochloride
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents C471 - Enzyme Inhibitor > C2087 - Inosine Monophosphate Dehydrogenase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors
Sofpironium bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes[1].
CID 54733074
3-fluoro-N-[4-[[4-(4-methoxyphenyl)-1-piperazinyl]-oxomethyl]phenyl]benzenesulfonamide
3-(4-{2-[2-(2-Bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
(4as,4br,10bs,12as)-12a-Methyl-1,3-Dioxo-2-(Pyridin-3-Ylmethyl)-1,2,3,4,4a,4b,5,6,10b,11,12,12a-Dodecahydronaphtho[2,1-F]isoquinolin-8-Yl Sulfamate
(2s,4s,5r)-2-Isobutyl-5-(2-Thienyl)-1-[4-(Trifluoromethyl)benzoyl]pyrrolidine-2,4-Dicarboxylic Acid
(2S)-6-(2,4-diamino-6-ethylpyrimidin-5-yl)-2-(3,5-difluorophenyl)-4-(3-methoxypropyl)-1,4-benzoxazin-3-one
Dactolisib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Methyl 2-[3-methoxy-2-[(5-phenyl-1,2-oxazole-3-carbonyl)amino]phenyl]-1,3-benzoxazole-4-carboxylate
2-[(4-{[([1,1-Biphenyl]-4-yl)methyl]amino}-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
(2S)-2-[[[4-[(2-amino-4-oxo-3H-quinazolin-6-yl)methyl-formylamino]phenyl]-hydroxymethyl]amino]pentanedioic acid
6-[3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
2-(4-Nitrophenoxy)-1-[4-(4-phenylphthalazin-1-yl)piperazin-1-yl]ethanone
[5-(4-Fluorophenyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[2-(3-pyridinyl)-1-piperidinyl]methanone
3-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoic acid (4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl) ester
(4-oxo-2,3-dihydro-1H-cyclopenta[c]chromen-7-yl) 4-methyl-2-[(4-methylphenyl)sulfonylamino]pentanoate
[2-(2-Methylpropylcarbamoylamino)-2-oxoethyl] 3-[(3,4-difluorophenyl)sulfonylamino]benzoate
3-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}benzimidazo[1,2-c]quinazoline-6(5H)-thione
7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid 2-methoxyethyl ester
1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
10-(2-Amino-ethylamino)-9-(3-chloro-phenyl)-2,2,5-trimethyl-1,4-dihydro-2H,9H-3-oxa-7-thia-6,9,11-tria za-benzo[c]fluoren-8-one
6-amino-1,3-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-hydroxy-5-methyl-3,4-dihydro[4,4-bipyrimidine]-2,2(1H,3H)-dione
An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.
dihydroascorbigen 5-O-beta-D-glucoside
A dihydroascorbigen hexoside in which the hexoside component is a beta-D-glucosyl residue attached at position 5 via a glycosidic bond.
butanoic acid [(4aS,5R,6R,7aR)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphorin-5-yl] ester
2-[(2R,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
1-[(2R,3R,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2S,4aR,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
N-[(2R,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
N-[(2S,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
1-[(2S,3R,6S)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
1-[(2R,3S,6R)-6-[2-(4-benzyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(3-chlorophenyl)urea
2-[(2R,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
N-[(2S,4aS,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
N-[(2S,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
N-[(2R,4aR,12aR)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
N-[(2R,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
1-(3-chlorophenyl)-3-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(1R,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(2S,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
2-[(2S,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
2-[(2R,4aS,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
N-[(2S,4aS,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
(3S)-2-tert-butylsulfinyl-4-[3-[3-(dimethylamino)prop-1-ynyl]phenyl]-3-(2-hydroxyethyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxylic acid
1-[(1S)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
[(1R)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-(3-chlorophenyl)-3-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
1-(3-chlorophenyl)-3-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(phenylmethyl)-1-triazolyl]ethyl]-3-oxanyl]urea
2-[(1S,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1S,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
2-[(1R,3S,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide
(3S)-4-[3-(1-cyclohexenyl)phenyl]-3-(2-hydroxyethyl)-N,N-dimethyl-2-methylsulfonyl-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
2-[(2R,4aS,12aR)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
2-[(2S,4aR,12aS)-8-(ethylsulfonylamino)-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-methoxyethyl)acetamide
N-[(2R,4aR,12aS)-2-[2-(dimethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-fluorobenzamide
[(1S)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1R)-7-methoxy-2-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-[(1R)-1-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1S)-2-[(3-chlorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-2-methoxyethanone
1-[(1R)-1-(benzenesulfonyl)-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
[(1S)-7-methoxy-9-methyl-1-(3-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-7-methoxy-9-methyl-1-(4-methylphenyl)sulfonyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
2-methoxyethyl (4S,7S)-7-(4-chlorophenyl)-4-(2-fluorophenyl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate
6-amino-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}hexanamide
methyl (2S)-2-[[(2Z)-2-(3,5-dioxo-4-phenyloxolan-2-ylidene)-2-phenylacetyl]amino]-3-phenylpropanoate
[(4aR,5R,6R,7aR)-6-[6-(butanoylamino)purin-9-yl]-2-hydroxy-2-oxo-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3,2]dioxaphosphinin-5-yl] butanoate
butanoic acid [(4aS,6S,7S,7aS)-2-hydroxy-2-oxo-6-[6-(1-oxobutylamino)-9-purinyl]-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-yl] ester
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[2-(hydroxymethyl)-3-oxo-1-phenylpropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(3-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-3-oxo-1-phenylbutyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
(2S)-2-azaniumyl-5-{[(2R)-1-[(carboxylatomethyl)amino]-1-oxo-3-{[(2-phenylethyl)carbamothioyl]sulfanyl}propan-2-yl]amino}-5-oxopentanoate
oxolan-2-ylmethyl 4-(6-chloro-4-oxochromen-3-yl)-2-methyl-5-oxo-4a,6,7,8-tetrahydro-4H-quinoline-3-carboxylate
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(2-hydroxy-2-methyl-3-oxo-1-phenylpropyl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-2-methyl-3-oxo-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxyphenyl)-2-methyl-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-3-oxo-1-phenylbutan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
[(2S,3S,5R,6R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydropyran-2-yl]oxy-cyclohexyl] 2-(1H-indol-3-yl)acetate
(4-Methoxybenzyl)thiocarbamic acid 4-O-(tri-O-acetyl-alpha-L-rhamnopyranoside)
2-deoxycytidine-thymidine dimer
A nucleoside analogue obtained by formal cyclodimerisation of 2-deoxycytidine and thymidine.
(2s,3r,4s)-4-{[(2r,3s,5s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h,3h,4h,4ah,9h-[1,3]dioxolo[4,5-j]phenanthridine-2,3,6,7-tetrol
(3s,4r,5s)-3,4-dihydroxy-5-[(1s)-2-hydroxy-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-3-(1h-indol-3-ylmethyl)oxolan-2-one
10-Formylfolic acid
-